Literature DB >> 33442131

Malaysian Consensus Statement for the Diagnosis and Management of Acromegaly.

Zanariah Hussein1, Mohamed Long Bidin2, Azmi Alias2, Muthukkumaran Thiagarajan2, Kartikasalwah Abdul Latif2, Jeyakantha Ratnasingam3, Wan Juani Wan Seman1, Azraai Nasruddin1.   

Abstract

In Malaysia, acromegaly is under-recognised with only 10-15% of the expected number of cases from prevalence estimates, having been diagnosed and managed in established endocrine centres with access to multidisciplinary care. This is mainly due to lack of awareness and standardised approach in diagnosing this disease resulting in delay in diagnosis and management with suboptimal treatment outcomes. This first Malaysian consensus statement on the diagnosis and management of acromegaly addresses these issues and is based on current best practices and latest available evidence so as to reduce the disease burden on acromegaly patients managed in the Malaysian healthcare system.
© 2019 Journal of the ASEAN Federation of Endocrine Societies.

Entities:  

Keywords:  Malaysia; acromegaly; consensus; growth hormone excess

Year:  2019        PMID: 33442131      PMCID: PMC7784186          DOI: 10.15605/jafes.034.01.03

Source DB:  PubMed          Journal:  J ASEAN Fed Endocr Soc        ISSN: 0857-1074


  64 in total

Review 1.  The changing face of acromegaly--advances in diagnosis and treatment.

Authors:  Antônio Ribeiro-Oliveira; Ariel Barkan
Journal:  Nat Rev Endocrinol       Date:  2012-06-26       Impact factor: 43.330

2.  Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners.

Authors:  Redzuan Zarool-Hassan; Helen M Conaglen; John V Conaglen; Marianne S Elston
Journal:  J Prim Health Care       Date:  2016-06

3.  Acromegaly: an endocrine society clinical practice guideline.

Authors:  Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2014-10-30       Impact factor: 5.958

Review 4.  Place of cabergoline in acromegaly: a meta-analysis.

Authors:  Laure Sandret; Patrick Maison; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

5.  Raloxifene decreases serum IGF-I in male patients with active acromegaly.

Authors:  Eleni V Dimaraki; Kathleen V Symons; Ariel L Barkan
Journal:  Eur J Endocrinol       Date:  2004-04       Impact factor: 6.664

6.  Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

Authors:  Renato Cozzi; Roberto Attanasio; Sandro Lodrini; Giovanni Lasio
Journal:  Clin Endocrinol (Oxf)       Date:  2004-08       Impact factor: 3.478

Review 7.  RADIOTHERAPY VERSUS RADIOSURGERY IN TREATING PATIENTS WITH ACROMEGALY: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Authors:  Abd Moain Abu Dabrh; Noor Asi; Wigdan H Farah; Khaled Mohammed; Zhen Wang; Magdoleen H Farah; Larry J Prokop; Laurence Katznelson; Mohammad Hassan Murad
Journal:  Endocr Pract       Date:  2015-08       Impact factor: 3.443

8.  Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.

Authors:  Jakob Dal; Ulla Feldt-Rasmussen; Marianne Andersen; Lars Ø Kristensen; Peter Laurberg; Lars Pedersen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto L Jørgensen
Journal:  Eur J Endocrinol       Date:  2016-06-08       Impact factor: 6.664

Review 9.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

10.  A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Authors:  Moises Mercado; Fatima Borges; Hakim Bouterfa; Tien-Chun Chang; Alberto Chervin; Andrew J Farrall; Attila Patocs; Stephan Petersenn; Jan Podoba; Mitra Safari; Joanna Wardlaw
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04-25       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.